Multiple Myeloma Drugs Market: Growth Opportunities led by Abbott Laboratories and AbbVie Inc. - Technavio
NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The multiple myeloma drugs market size is estimated to grow by USD 6,419.94 million during 2021-2026, at a CAGR of 5.9%. The growth of the market will be driven by the growing incidence of multiple myeloma. Furthermore, the emergence of nanomedicine platforms is expected to boost market growth.
The report extensively covers the multiple myeloma drugs market segmentation by therapy (targeted therapy, biologic therapy, chemotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-pharmacy), and geography (North America, Europe, Asia, and Rest of the World (ROW).Request A Free Sample Report
Multiple Myeloma Drugs Market - Vendors
The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.?
Amgen Inc.
AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Bristol Myers Squibb Co.
Cipla Ltd.
Daiichi Sankyo Co. Ltd.
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
Fresenius SE and Co. KGaA
GlaxoSmithKline Plc
Johnson and Johnson
Merck and Co. Inc.
Novartis AG
Product Insights and News
Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.
AbbVie Inc.: The company offers multiple myeloma drugs such as Vysis 13q34 SpectrumGreen FISH Probe Kit.
Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.
For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.
North America is estimated to account for 36% of the market's growth during the forecast period. The growing prevalence of various cancer indications, including multiple myeloma and non-Hodgkin's lymphoma is driving the growth of the regional market. The market in North America is further benefitted from the availability and high sales of approved multiple myeloma drugs. The patent expiry of a major drug brand has resulted in the development of generic versions of the drug by various large- and mid-sized pharmaceutical vendors in the region. This is contributing to the growth of the multiple myeloma drugs market in North America.
The targeted therapy segment is estimated to contribute significantly to the global market's growth during the forecast period. The increasing demand for targeted therapies is driven by the efficacy of the therapy in blocking the action of a substance in myeloma cells that disrupt proteins. This action helps in killing the myeloma cells. Also, the increasing number of drug approvals for the treatment of multiple myeloma is fueling the growth of the segment.
Additionally, recent approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. - Download a free sample report
What are the key data covered in this multiple myeloma drugs market report?
CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the multiple myeloma drugs market between 2023 and 2027
Precise estimation of the size of the multiple myeloma drugs market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the multiple myeloma drugs market industry across APAC, North America, Europe, Middle East and Africa, and South America
Thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of multiple myeloma drugs market vendors
Compounding Pharmacy Market by Product and Geography - Forecast and Analysis 2022-2026: The compounding pharmacy market share is expected to increase by USD 1.5 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 2.15%.
Proteasome Inhibitors Market by Product and Geography - Forecast and Analysis 2022-2026: According to Technavio's analyst, the proteasome inhibitors market size is expected to be valued at USD 2.20 billion by 2026 with a CAGR of 7.4%.
Multiple Myeloma Drugs Market Scope
Report Coverage
Details
Page number
167
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 5.9%
Market growth 2023-2027
USD 6419.94 million
Market structure
Fragmented
YoY growth (%)
5.76
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 36%
Key countries
US, Canada, Germany, UK, and China
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc.
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of contents:
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary ? Chart on Market Overview
Exhibit 02: Executive Summary ? Data Table on Market Overview
Exhibit 03: Executive Summary ? Chart on Global Market Characteristics
Exhibit 04: Executive Summary ? Chart on Market by Geography
Exhibit 05: Executive Summary ? Chart on Market Segmentation by Therapy
Exhibit 06: Executive Summary ? Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary ? Chart on Incremental Growth
Exhibit 08: Executive Summary ? Data Table on Incremental Growth
Exhibit 09: Executive Summary ? Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global multiple myeloma drugs market 2017 - 2021
Exhibit 18: Historic Market Size ? Data Table on Global multiple myeloma drugs market 2017 - 2021 ($ million)
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...
Ball Corporation's board of directors (the "Board") today declared a cash dividend of 20 cents per share, payable June 17, 2024, to shareholders of record as of June 3, 2024. In addition, the board also approved the repurchase by the company of up...
As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the...